S&P 500   4,625.27 (-0.64%)
DOW   34,897.55 (-0.68%)
QQQ   398.67 (-0.26%)
AAPL   159.56 (-0.42%)
MSFT   336.37 (-0.08%)
FB   336.28 (-0.52%)
GOOGL   2,901.59 (-0.31%)
AMZN   3,574.85 (+0.37%)
TSLA   1,140.94 (+0.35%)
NVDA   333.33 (-0.13%)
BABA   130.23 (-1.05%)
CGC   10.88 (-1.63%)
AMD   163.53 (+1.00%)
GE   97.13 (-1.29%)
MU   85.90 (-0.28%)
T   23.68 (-0.88%)
F   19.50 (-0.86%)
DIS   146.40 (-0.95%)
AMC   36.40 (-1.19%)
PFE   52.71 (+0.59%)
BA   196.12 (-1.20%)
S&P 500   4,625.27 (-0.64%)
DOW   34,897.55 (-0.68%)
QQQ   398.67 (-0.26%)
AAPL   159.56 (-0.42%)
MSFT   336.37 (-0.08%)
FB   336.28 (-0.52%)
GOOGL   2,901.59 (-0.31%)
AMZN   3,574.85 (+0.37%)
TSLA   1,140.94 (+0.35%)
NVDA   333.33 (-0.13%)
BABA   130.23 (-1.05%)
CGC   10.88 (-1.63%)
AMD   163.53 (+1.00%)
GE   97.13 (-1.29%)
MU   85.90 (-0.28%)
T   23.68 (-0.88%)
F   19.50 (-0.86%)
DIS   146.40 (-0.95%)
AMC   36.40 (-1.19%)
PFE   52.71 (+0.59%)
BA   196.12 (-1.20%)
S&P 500   4,625.27 (-0.64%)
DOW   34,897.55 (-0.68%)
QQQ   398.67 (-0.26%)
AAPL   159.56 (-0.42%)
MSFT   336.37 (-0.08%)
FB   336.28 (-0.52%)
GOOGL   2,901.59 (-0.31%)
AMZN   3,574.85 (+0.37%)
TSLA   1,140.94 (+0.35%)
NVDA   333.33 (-0.13%)
BABA   130.23 (-1.05%)
CGC   10.88 (-1.63%)
AMD   163.53 (+1.00%)
GE   97.13 (-1.29%)
MU   85.90 (-0.28%)
T   23.68 (-0.88%)
F   19.50 (-0.86%)
DIS   146.40 (-0.95%)
AMC   36.40 (-1.19%)
PFE   52.71 (+0.59%)
BA   196.12 (-1.20%)
S&P 500   4,625.27 (-0.64%)
DOW   34,897.55 (-0.68%)
QQQ   398.67 (-0.26%)
AAPL   159.56 (-0.42%)
MSFT   336.37 (-0.08%)
FB   336.28 (-0.52%)
GOOGL   2,901.59 (-0.31%)
AMZN   3,574.85 (+0.37%)
TSLA   1,140.94 (+0.35%)
NVDA   333.33 (-0.13%)
BABA   130.23 (-1.05%)
CGC   10.88 (-1.63%)
AMD   163.53 (+1.00%)
GE   97.13 (-1.29%)
MU   85.90 (-0.28%)
T   23.68 (-0.88%)
F   19.50 (-0.86%)
DIS   146.40 (-0.95%)
AMC   36.40 (-1.19%)
PFE   52.71 (+0.59%)
BA   196.12 (-1.20%)
NASDAQ:INKT

MiNK Therapeutics Stock Forecast, Price & News

$13.28
-6.73 (-33.63%)
(As of 11/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.18
$19.64
50-Day Range
N/A
52-Week Range
$11.20
$22.16
Volume
102,079 shs
Average Volume
67,582 shs
Market Capitalization
$432.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive INKT News and Ratings via Email

Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


MiNK Therapeutics logo

About MiNK Therapeutics

MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York.

Headlines

MiNK Therapeutics (NASDAQ:INKT) Stock Price Down 7.2%
November 29, 2021 |  americanbankingnews.com
MiNK Therapeutics (NASDAQ:INKT) Trading Up 7.6%
November 24, 2021 |  americanbankingnews.com
MiNK Therapeutics (NASDAQ:INKT) Shares Down 8.6%
November 23, 2021 |  americanbankingnews.com
MiNK Therapeutics (NASDAQ:INKT) Shares Gap Down to $16.18
November 17, 2021 |  americanbankingnews.com
MiNK Therapeutics (NASDAQ:INKT) Shares Gap Up to $17.43
November 16, 2021 |  americanbankingnews.com
MiNK Therapeutics (NASDAQ:INKT) Shares Up 5.6%
November 12, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INKT
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$432.80 million
Optionable
Not Optionable

Company Calendar

Today
11/30/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

929th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

140th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












MiNK Therapeutics (NASDAQ:INKT) Frequently Asked Questions

Is MiNK Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MiNK Therapeutics stock.
View analyst ratings for MiNK Therapeutics
or view top-rated stocks.

What price target have analysts set for INKT?

4 brokerages have issued 1 year target prices for MiNK Therapeutics' shares. Their forecasts range from $24.00 to $30.00. On average, they expect MiNK Therapeutics' stock price to reach $26.67 in the next year. This suggests a possible upside of 100.8% from the stock's current price.
View analysts' price targets for MiNK Therapeutics
or view top-rated stocks among Wall Street analysts.

When did MiNK Therapeutics IPO?

(INKT) raised $43 million in an initial public offering on Friday, October 15th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share.

What is MiNK Therapeutics' stock symbol?

MiNK Therapeutics trades on the NASDAQ under the ticker symbol "INKT."

When did the company's quiet period expire?

MiNK Therapeutics' quiet period expired on Wednesday, November 24th. MiNK Therapeutics had issued 3,333,334 shares in its initial public offering on October 15th. The total size of the offering was $40,000,008 based on an initial share price of $12.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of MiNK Therapeutics?

Shares of INKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MiNK Therapeutics' stock price today?

One share of INKT stock can currently be purchased for approximately $13.28.

How much money does MiNK Therapeutics make?

MiNK Therapeutics has a market capitalization of $432.80 million.

What is MiNK Therapeutics' official website?

The official website for MiNK Therapeutics is www.minktherapeutics.com.

How can I contact MiNK Therapeutics?

The company can be reached via phone at 212-994-8250 or via email at [email protected].


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.